Alopecia areata causes the immune system to attack hair follicles, creating smooth, round patches of hair loss on the scalp or body. About 2% of people develop it at some point, often starting in childhood or young adulthood. Until 2022, no FDA-approved treatments existed; now two JAK inhibitors are approved for severe cases.
What's actually going on in research
Trials are testing oral and topical JAK inhibitors at different doses and for milder disease, biologics that block specific immune signals like IL-15, and combination approaches. Researchers are also studying what triggers the immune attack, why some people respond better than others, and whether earlier treatment prevents progression to more extensive hair loss.
JAK inhibitors expanding
Baricitinib and ritlecitinib are FDA-approved for severe alopecia areata, and trials are testing whether lower doses work for patchy disease. Topical JAK inhibitors may offer an option for people with limited hair loss who want to avoid systemic treatment.
Biologics targeting immune signals
Studies are testing drugs that block IL-15, IL-2, and other immune proteins involved in the attack on hair follicles. These may work for people who don't respond to JAK inhibitors or who can't tolerate them.
Combination strategies
Some trials are pairing immune-suppressing drugs with treatments that stimulate hair growth directly. The goal is to quiet the immune attack while encouraging follicles to regrow hair.
What to know before you search
Eligibility typically depends on how much scalp hair has been lost, how long the hair loss has lasted, and whether you've tried other treatments like steroid injections.
What types of trials are currently open
- JAK inhibitor trials — Testing oral and topical JAK inhibitors for different severities of alopecia areata, often comparing doses or treatment durations.
- Biologic trials — Testing monoclonal antibodies that block specific immune pathways thought to drive hair loss in alopecia areata.
- Combination trials — Pairing immune-modulating drugs with topical hair growth stimulants to see if the combination produces better regrowth.
- Pediatric trials — Testing treatments specifically in children and adolescents, who make up a large portion of people with alopecia areata.
- Natural history studies — Following people over time to understand how alopecia areata progresses, what predicts regrowth, and how quality of life is affected.
Recently added Alopecia Areata trials
Dual Modality Treatment of Androgenic Alopecia With KeraFactor® Solution and Revian® LED Light Therapy
This single-center, prospective, randomized, placebo-controlled interventional study will evaluate the safety and efficacy of KeraFactor scalp-stimulating solution and the Revian Red wireless smart cap, alone and in combination, for the treatment of female androgenic alopecia. Forty female subjects aged 35 to 55 with clinically diagnosed androgenic alopecia will be randomized into four treatment arms and followed for 24 weeks. The primary objective is to determine whether combination therapy produces greater improvement in hair growth from baseline to 6 months compared with solution alone, device alone, or placebo. Secondary outcomes include changes in hair density, hair fiber diameter, interfollicular distance, terminal-to-vellus hair ratio, patient satisfaction, and safety/tolerability.
UV-Trichoscopic Red Fluorescence in Alopecia Areata
The goal of this observational study is to learn whether red fluorescence seen with ultraviolet (UV) trichoscopy is related to disease findings and treatment response in adults with limited plaque-type alopecia areata. Trichoscopy is a close-up imaging method used to examine the hair and scalp. The study will investigate whether the amount of red fluorescence at the beginning of the study is related to how soon hair starts to grow back, how much hair regrows, and how trichoscopic findings change during follow-up. Participants for whom intralesional corticosteroid treatment has been planned as part of their regular medical care will have standard trichoscopic and UV-trichoscopic images taken of the affected scalp area. They will be followed at weeks 4, 8, and 12, when hair regrowth and changes in scalp and hair findings will be evaluated. Researchers will measure red fluorescence in the images and examine whether it is related to treatment response over time.
Find Alopecia Areata trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.